US equities |
NVDA $221.30 ▼-3.16% MU $914.13 ▼-4.10% AAPL $342.96 ▲+0.50% AMD $570.82 ▼-5.73% META $737.54 ▼-3.27% MSFT $533.69 ▼-1.80% TSLA $367.16 ▼-2.15% SPCX $152.16 ▼-2.80%
FinancialContent

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

19.25 +0.63 (+3.38%)
Delayed Quote Updated: 4:00 PM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
19 20 Next >
News headline image
Delaware District Court Rules in Favor of Acadia on Formulation Patent Construction (Markman) Claims Regarding NUPLAZID® (pimavanserin)
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Soars To A Four-Month High After Winning A Patent Battle For Its Biggest Drug ↗
MSN Labs lost out in a summary judgement to knock off Acadia's Nuplazid. 
Via Investor's Business Daily
Topics Intellectual Property
News headline image
Delaware Federal District Court Rules in Favor of Acadia Pharmaceuticals in NUPLAZID® (pimavanserin) Patent Litigation
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
What's Going On With Acadia Pharmaceuticals Stock? ↗
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) shares are trading higher Wednesday after the company won summary judgement in a patent suit regarding its Nuplazid drug. What To Know: 
Via Benzinga
Topics Intellectual Property
News headline image
Analyst Ratings for ACADIA Pharmaceuticals ↗
 
Via Benzinga
News headline image
What 7 Analyst Ratings Have To Say About ACADIA Pharmaceuticals ↗
 
Via Benzinga
News headline image
Analyst Ratings for ACADIA Pharmaceuticals ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Leading the Way in Wednesday Trading Based on Percentage Gain
Via Investor Brand Network
News headline image
ACADIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Acadia Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Acadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Why Acadia Pharmaceuticals Stock Is Rising Today ↗
An analyst upgrade is sparking a rally in the drugmaker's shares today. 
Via The Motley Fool
News headline image
2 Growth Stocks I'd Buy on the Dip ↗
These two growth stocks could be worthwhile buy-and-holds. 
Via The Motley Fool
News headline image
Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals Announces Change in Research and Development Leadership
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
3 Biotech Stocks With the Strongest Clinical Pipelines ↗
Many industry heavyweights are on the hunt for fresh new ideas -- great news for biotech stocks to buy with strong pipelines. 
Via InvestorPlace
News headline image
Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Acadia Pharmaceuticals to Participate in the Guggenheim Securities 5th Annual Inflammation & Immunology Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals Announces the Rett Sibling Scholarship Program
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 2, 2023
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2023 ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023 ↗
 
Via Benzinga
News headline image
Electronic Arts To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Tuesday ↗
JP Morgan increased ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) price target from $29 to $32. JP Morgan analyst Tessa Romero upgraded the stock from Neutral to Overweight. ACADIA Pharmaceuticals shares... 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Why CarMax Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Bionomics Limited (NASDAQ: BNOX) shares jumped 308% to $4.00 after the company announced the ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
19 20 Next >